Limb-girdle muscular dystrophy type 2C (LGMD2C) is a genetic disorder belonging to the group of muscular dystrophies characterized by degeneration of skeletal muscles, which leads to progressive weakness and atrophy of the limb muscles. The main feature of this disease is the lesion of the deltoid, levator scapula and pelvic muscles. The onset of the disease can be manifested in childhood or adulthood, depending on the clinical variant. The characteristic pathogenesis of LGMD2C is due to impaired expression of dystrophin, which causes single mutational changes in genes associated with the structural integrity of the muscle cell.
History of the disease and interesting historical facts
Limb-girdle muscular dystrophy was first described in the scientific literature in the 1970s, when scientists began to associate gene mutations with various forms of muscular dystrophy. In particular, LGMD2C was identified as a distinct form based on clinical manifestations and hereditary aspects. Research into genetic predisposition has continued for several decades, leading to a deeper understanding of the disease mechanism. Individual cases of the disease have been described in closely related families, which has contributed significantly to the understanding of its hereditary nature.
Epidemiology
The epidemiology of the final form of limb-girdle muscular dystrophy shows a frequency of disease occurrence in a number of ethnic groups. Approximately 1 in 20,000-60,000 people may suffer from the disease, while the frequency of the LGMD2C variant varies depending on the population. For example, in some regions of Europe, cases are much less common than in countries with a high concentration of inbreeding. Studies show that the highest incidence of the variant is observed in areas with limited genetic variability.
Genetic predisposition to this disease
The genetic basis of LGMD2C is linked to mutations in the DYSF gene, which codes for the protein dysfusin, which is essential for muscle cell structure and function. Various mutations in this gene have been reported to cause a variety of clinical manifestations, including both mild and severe forms of the disease. In addition to DYSF, other associated genes may be involved that also affect the modulation of muscle growth and the maintenance of muscle cell integrity.
Risk factors for the development of this disease
The main risk factors for developing limb-girdle muscular dystrophy include:
- Genetic predisposition - the presence of sick relatives, especially in the case of close kinship.
- Ethnicity - diseases are more common among certain ethnic groups.
- Age of onset of first symptoms - the earlier signs of the disease appear, the higher the risk of its progression.
- Unknown environmental factors that may influence the manifestation of the disease.
Diagnosis of this disease
Diagnosis of the final form of limb-girdle muscular dystrophy involves a comprehensive approach:
- Symptoms vary, but often include progressive muscle weakness, especially in the shoulder girdle and pelvic area.
- Laboratory tests include a blood test for creatine kinase levels, which may be significantly elevated.
- Radiological studies such as MRI can assess the condition of muscle tissue and the presence of atrophic areas.
- Genetic testing to confirm diagnoses and identify mutations in genes such as DYSF.
- Differential diagnosis is important to exclude other forms of myopathy and dystrophy.
Treatment
Treatment of limb-girdle muscular dystrophy requires a comprehensive approach:
- General treatment: Pathogenetic therapy is aimed at slowing the progression of the disease and maintaining muscle function.
- Pharmacological treatment: Includes the use of corticosteroids to reduce inflammation and slow muscle atrophy.
- Surgical treatment: May be necessary to correct skeletal deformities and improve functional activity.
- Other treatments: Physical therapy and rehabilitation play an important role in maintaining muscle function and improving patients' quality of life.
List of medications used to treat this disease
- Corticosteroids (eg, prednisolone)
- Creatine
- Drugs that improve muscle metabolism (eg, midazolam)
- Biologics (some studies have shown promising results)
Disease monitoring
Monitoring the condition of patients with limb-girdle muscular dystrophy includes regular follow-up examinations aimed at:
- Assessment of the functional capabilities of patients.
- Monitoring disease progression and possible complications such as contractures or respiratory problems.
- Prognosis – The course of the disease varies, but many patients require lifelong supportive care.
Age-related features of the disease
Depending on age, the clinical manifestations and course of LGMD2C can vary greatly:
- In children, the disease may manifest itself at an early stage, leading to early loss of motor skills.
- In adolescents, symptoms may be more pronounced, requiring close monitoring of physical development.
- In adults, the disease usually progresses more slowly, but close monitoring is also necessary to prevent possible complications.
Questions and Answers
- What is the main cause of limb-girdle muscular dystrophy type 2C? The main cause is mutations in the DYSF gene.
- What are the most typical symptoms of this disease? The main symptoms are progressive weakening of the muscles of the shoulder girdle and pelvic area.
- Is it possible to stop the progression of the disease? It is impossible to completely stop the progression, but adequate treatment can slow it down.
- What treatment is most effective for this disease? An integrated approach, including drug and non-drug treatment, gives the best results.
- Is there a chance that the disease can be passed on to children? Yes, the disease is inherited in a recessive manner, and the risk of transmission depends on the genetic predisposition of the parents.
Advice from Dr. Oleg Korzhikov
For patients with limb-girdle muscular dystrophy, Dr. Oleg Korzhikov recommends:
- Undergo regular check-ups to monitor your health and identify possible complications.
- Maintain physical activity within the limits of the body's capabilities to slow down muscle atrophy.
- Consult your doctor for individual treatment, as each form of the disease is unique.
- Discuss the results of genetic tests with your healthcare provider to understand the possible risks to future generations.
Following these recommendations will help improve your quality of life and slow the progression of the disease.
